Associations between Sympathetic Activity, Plasma Concentrations of Renin, Aldosterone, and Parathyroid Hormone, and the Degree of Intractability of Blood Pressure Control in Hemodialysis Patients by Hong, Zoong-Rock et al.
INTRODUCTION
Hypertension (HT), either as a primary cause or consequ-
ence of renal failure, is a major risk factor for high cardiovas-
cular morbidity in uremic patients (1). HT in patients with
end stage renal disease (ESRD) who are on hemodialysis (HD)
is defined by either a systolic blood pressure (SBP) >150
mmHg or a diastolic blood pressure (DBP) >85 mmHg (2).
HT occurs in 70-90% of HD patients, which is a substan-
tially higher incidence than that in the general population
(2-4). Several factors have been reported to be involved in
the pathogenesis of HT in HD patients, most of which have
been categorized according to whether they are volume-de-
pendent or volume-independent based on the response to
ultrafiltration, i.e., in terms of the response to volume removal
and/or dietary sodium restriction. Volume-independent fac-
tors are characterized by increased activity of the rennin an-
giotensin aldosterone system (RAAS) and a limited rate of
blood pressure (BP) reduction by volume reduction. 
Theoretically, it should be relatively easy to control BP in
most of HD patients by ensuring that patients maintain a
target body weight during the HD treatment process, which
is estimated by the dry weight. However, contrary to the afore-
mentioned theory, most HD patients (-75%) require anti-
hypertensive drugs to control BP (5). Many reasons have been
proposed to explain this discrepancy between the theory and
practice of regulating BP in HD patients. The reasons could
be explained by the activation of volume-independent factors
such as the RAAS, an overactive sympathetic nervous system,
impaired vasodilatation, elevated erythropoietin (EPO), and
secondary hyperparathyroidism.
The best way to avoid HT in HD patients would be to
identify and remove those factors that play a dominant role.
However, in clinical practice, it is difficult to determine which
factors are responsible for HT, especially when the control of
BP is intractable even in the face of substantial weight loss
during HD. In addition, the responses of HD patients to anti-
hypertensive therapy are highly variable. 
Several causes seem to be involved in its difficulty to deter-
mine which single factor might cause HT in ESRD patients.
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Associations between Sympathetic Activity, Plasma Concentrations of
Renin, Aldosterone, and Parathyroid Hormone, and the Degree of
Intractability of Blood Pressure Control in Hemodialysis Patients
This study was designed to examine how such factors as hemodialysis parameters,
body mass index, renin and aldosterone concentrations, sympathetic nervous activi-
ty, and parathyroid hormone concentrations are associated with the control of hyper-
tension in hemodialysis patients. Hemodialysis patients (n=114) were grouped into
four categories. Group 1 had normal BP without antihypertensive medication. Group
2 needed one antihypertensive drug, Group 3 needed combination of two or three
categories of antihypertensive drugs without minoxidil. Group 4 needed more than
three categories of antihypertensive drugs including minoxidil. Parathyroid hormone,
2-microglobulin, renin and aldosterone, epinephrine, norepinephrine, and hemo-
dialysis parameters were measured. The fractional clearance of urea as Kt/V urea
was significantly lower in Group 3 and Group 4 than in Group 2 (p<0.01). Concen-
trations of parathyroid hormone were significantly higher in Group 4 than the other
groups (p<0.01). Pre-hemodialysis norepinephrine concentrations were significantly
higher in Group 4 than the other groups (p<0.05). Traditional factors associated
with hypertension did not seem to be relevant to the degree of hypertension in
hemodialysis patients in the present study. In conclusion, poor Kt/V urea, elevated
parathyroid hormone concentrations, and elevated concentrations of plasma nore-
pinephrine seemed to be the factors that might be associated with control of hyper-
tension in hemodialysis patients. 
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First, the multiple physiological factors that can cause HT may
be distinct from the factors that maintain normal BP. Second,
factors may interact with one another. For example, in some
HT patients, there is a direct correlation between plasma renin
activity and plasma concentrations of norepinephrine (NEP)
(6). Third, hormones that directly regulate BP, such as an-
giotensin, also have stimulatory effects on the sympathetic
nervous system, including enhancing sympathetic outflow
and/or acting on stimulatory presynaptic receptors (7-12).
Collectively, the observations of associations among hyper-
parathyroidism, impairment of vitamin D metabolism, and
overactivity of the sympathetic nervous system in ESRD
patients suggest that the RAAS, the parathyroid hormone
(PTH)-vitamin D-calcium axis, and sympathetic activity
interact to make it difficult for ESRD patients to regulate
their BP. We guess that the difficulty in the regulation of
hypertension was affected by multiple factors, so we investi-
gated which factors have effects on HT control according to
the need of hypertensive drug. 
The present study was carried out to analyze the associa-
tions between the degree of HT and various factors in ESRD
patients who underwent HD.
MATERIALS AND METHODS
ESRD patients (n=114; 61 males, 53 females; age=53.1±
13.0 yr, mean body mass=56.5±10.9 kg; mean height=
163.6±9.1 cm) who had undergone HD periodically for at
least 6 months (mean duration of HD=117±58.4 months)
were enrolled in this study. All patients provided informed
consent, and the study protocol was approved by the Ethics
Committee of Soonchunhyang University Cheonan Hospi-
tal, Korea. All patients underwent HD for 12-15 hr per week
using a dialyzer (polyamide membrane; Polyflux 6L, Gam-
bro, Gambro Dialysatoren, Hechingen, Germany). The flow
rate of the dialysate was fixed at 500 mL/min during each
HD session. The blood flow rate was 250-300 mL/min. The
variable-volume, single-pool urea kinetic model was used to
for dialysis prescriptions and to monitor dietary protein intake
(quantified as the normalized protein catabolic rate; nPCR).
The dose of HD was described as the fractional clearance of
urea as a function of its distribution volume (Kt/V urea).
Among the 114 patients, there were 35 cases of diabetes
mellitus (30.7%), 37 cases of HT (32.5%), 28 cases of chronic
glomerulonephritis (24.6%), 4 cases of polycystic kidney dis-
ease (3.5%), 3 cases of renal tuberculosis (2.6%), and 7 cases
with an unknown cause of ESRD (6.1%). There was no differ-
ence in the distribution of underlying disease among Group
1-4. 
The blood pressure and heart rate were measured on the
opposite arm of vascular access before and after HD, and the
means of the results of last two weeks were used as data. 
The target SBP and DBP was 150 and 85 mmHg, respec-
tively. All patients were placed on a low-sodium diet and inter-
dialytic weight gain was required to be less than 3.0 kg. The
target weight for each patient was established according to the
maximum endurance of volume depletion by ultrafiltration.
In terms of the definition of dry weight as a point from
which BP goes down, a large number of patients had not
reached the point. In cases where the BP could not be regu-
lated by employing a low-sodium diet to control body weight,
antihypertensive drugs were prescribed as follows. The cate-
gories of antihypertensive drugs included  -blockers (ate-
nolone, 50 mg/tablet), calcium channel blockers (splendil
[felodipine], 5 mg/tablet; Norvasc [amlodipine camsylate],
5 mg/tablet), angiotensin-converting enzyme (ACE) inhibi-
tors (enalapril, 10 mg/tablet), and angiotensin II receptor
blockers (ARB) (Aprovel [irbesartan], 150 mg/tablet; Coz-
zar [losartan], 100 mg/tablet). Only one drug from each cat-
egory was prescribed. The ACE inhibitor and the ARB were
regarded as belonging to the same category. When BP could
not be controlled even when the dose of the initially pre-
scribed drug was doubled, an additional drug from another
category was prescribed rather than increasing the dose of
the drug prescribed initially. For patients who were prescribed
with antihypertensive drugs from more than two categories,
the drugs were prescribed without the vasodilator, minoxi-
dil (5 mg/tablet). Minoxidil was prescribed only for cases in
which BP remained elevated despite treatment with antihy-
pertensive drugs from three categories. The first class of anti-
hypertensive drug prescribed was either ARB (16 cases), cal-
cium channel blockers (8 cases), the  -blocker (7 cases), or
the ACE inhibitor (1 case). The number of the patients who
used an antihypertensive drug (regardless of whether they
used other category of antihypertensive drugs) was 61 for
ARB, 58 for calcium channel blockers, 40 for the  -block-
er, 12 for the vasodilator, and 7 for the ACE inhibitor.
Patients were classified into four groups according to the
aforementioned drug treatment regimen to reflect the diffi-
culty in the control of HT as follows: In Group 1, BP was
within the normal range and no antihypertensive drugs were
prescribed; in Group 2, control of BP required antihyperten-
sive drugs from only one category; in Group 3, two or three
categories of antihypertensive drug were required to control
BP, but not minoxidil; and in Group 4, antihypertensive
drugs from more than three categories were required to con-
trol BP, including minoxidil. The application of these crite-
ria resulted in 22 cases (10 male and 12 female) in Group 1,
32 (14 male and 18 female) in Group 2, 46 (25 male and 21
female) in Group 3, and 14 (14 male and 2 female) in Group 4.
Blood samples were collected prior to HD (pre-HD) to
measure CBC, blood chemistry, electrolytes, and concentra-
tions of PTH,  2-microglobulin, renin, and aldosterone.
Blood samples were collected from the antecubital vein con-
tralateral to the site at which the vascular access was gained
for HD. Samples were collected immediately prior to the
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sion to measure pre- and post-HD concentrations of renin,
aldosterone, epinephrine (EP), and NEP, respectively. All
samples were stored at -70℃ until analysis. Commercially
available radioimmunoassay kits were used to measure plas-
ma concentrations of renin (Renin Riabead; Dainabot, Tokyo,
Japan), aldosterone (Immunotech SA, Marseille, France), EP
and NEP (IBL, Hamburg, Germany), intact PTH (iPTH)
(PTH-120 MIN IRMA; BioSource Europe SA, Belgium),
and  2-microglobulin ( 2-microglobulin radioimmunoas-
say kit; Abbott Laboratories, Chicago, IL, U.S.A.).
Statistical analyses were performed with SPSS for Windows
(version 12.0; SPSS, Chicago, IL, U.S.A.). The duration of
HD, and plasma concentrations of EPO,  2-microglobulin,
iPTH, aldosterone, renin, EP, and NEP were presented as
means±SEM. The values of the remaining parameters were
presented as means±SD. To examine associations between
these parameters and the severity of HT, we analyzed differ-
ences in the concentrations of iPTH, aldosterone, renin, EP,
and NEP as well as the aldosterone/renin ratio among the
groups of patients (Groups 1-4) using chi-squared tests (for
categorical variables) and Kruskal-Wallis tests or ANOVA
(analysis of variance). If the results were significant by AN-
OVA, we analyzed the difference among the groups based
on Turkey’s multiple comparison test. 
RESULTS
There were no significant associations between the follow-
ing parameters and the degree of HT: age, duration of HD,
dry weight, height, BMI, pre- and post-HD body weight,
interdialytic weight gain, blood flow during HD, ultrafiltra-
tion during HD, nPCR, and the concentrations of Hb, Hct,
EPO doses, albumin, calcium, phosphorus, total cholesterol,
triglycerides,  2-microglobulin, and HCO3. However, the
Kt/V urea was significantly lower (p<0.01) in Groups 3 (1.49
±0.29) and 4 (1.40±0.23) compared to Group 2 (1.75±
0.40) (Table 1, Fig. 1). Pre- and post-HD SBP was signifi-
cantly higher in Groups 3 and 4 compared to Groups 1 and 2
(p<0.01), but there was no such difference in DBP. The pre-
HD (p<0.01) and post-HD (p<0.02) heart rate was signifi-
cantly higher in Groups 3 and 4 than in Group 1 (Table 2).
Changes in the concentrations of iPTH, aldosterone, renin,
aldosterone, EP, and NEP were not associated with the degree
of HT (data not shown). The concentration of iPTH was
significantly higher in Group 4 than in Groups 1-3 (p<0.01;
Table 3, Fig. 2). The pre-HD (p<0.01) and post-HD (p<0.01)
aldosterone concentrations were significantly lower in Groups
3 and 4 compared to Groups 1 and 2. Neither pre- and post-
HD renin concentrations nor pre- and post-HD aldosterone/
Group 1 Group 2 Group 3 Group 4 p*
Age (yr) 53.2±13.8 56.8±10.6 52.9±12.8 45.2±15.3 0.52
HD duration 64.4±7.4 61.4±7.9 52.4±6.6 62.0±10.1 0.65
Dry weight (kg) 53.8±9.4 57.5±11.4 56.6±12.1 58.1±6.9 0.61
Height (cm) 163.2±9.1 162.2±8.6 163.8±9.7 167.4±8.4 0.37
BMI (kg/m
2) 20.2±3.0 21.6±3.0 21.0±3.3 20.8±2.6 0.46
Body weight (kg)
Pre-HD 56.9±10.0 60.2±12.1 60.4±13.0 62.1±6.5 0.57
Post-HD 54.4±9.5 57.6±11.6 57.7±12.7 58.6±6.3 0.63
Weight gain (kg) 2.8±1.1 2.7±1.0 2.8±0.8 3.3±1.0 0.32
Blood flow 281.7±34.8 291.8±18.1 288.2±25.1 289.6±21.2 0.54
Ultrafiltration 3.3±0.8 3.2±0.9 3.3±0.9 3.6±1.0 0.40
Kt/V urea 1.60±0.26 1.75±0.40 1.49±0.29 1.40±0.23 <0.01
T
� a, b a b b
Npcr 0.86±0.26 0.82±0.24 0.84±0.26 0.75±0.14 0.62
Table 1. Comparison of dialysis-related data among groups
*Statistical significance was tested by one-way analysis of variances among groups; 
�
The same letters indicate a difference not significant between
groups based on Turkey’s multiple comparison test.
HD, hemodialysis; BMI, body mass index; Kt/V urea, the fractional clearance of urea as a function of its distribution volume.
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Fig. 1. Comparison of the fractional clearance of urea as a func-
tion of its distribution volume (Kt/V urea) among groups. The value
of Kt/V urea was significantly lower in Groups 3 and 4 (*) than in
Group 2 tested by one-way analysis of variances (p<0.01) and
Turkey’s multiple comparison test. iPTH, intact parathyroid hor-
mone.
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renin ratio were significantly different among groups (Table
3). The pre- and post-HD EP concentration was 39.9±4.9
vs. 43.5±4.6 in Group 1, 41.5±2.6 vs. 32.9±1.9 in Group
2, 43.0±3.4 vs. 34.5±3.2 in Group 3, and 44.5±4.5 vs.
33.7±2.4 in Group 4, (p=0.91 for comparison of pre-HD
EPO concentration among Groups 1-4; p=0.16 for post-HD
EPO concentration). The pre-HD NEP concentration was
significantly higher in Group 4 than in Groups 1 and 3 (p<
0.05), but was not significantly different in Group 2 (Table
3, Fig. 3). There was a significant correlation between pre-
and post-HD NEP concentrations (p<0.01), but there was
no correlation between pre-HD NEP concentrations and any
of renin, aldosterone, and PTH concentrations.
Neither the pre- nor post-HD renin activity was significant-
ly different between patients who did and those who did not
use the ACE inhibitors, ARB, the  -blocker, calcium chan-
nel blockers, and minoxidil. However, both pre- and post-HD
aldosterone concentrations were significantly lower in patients
who used ARB compared to those who did not (p<0.01). Sim-
ilarly, pre-HD aldosterone concentrations were significantly
lower in patients who used the calcium channel blockers com-
pared to those who did not (p<0.01; Table 4). Post-HD EP
concentrations were significantly higher in patients who did
not use minoxidil compared to those who did use this drug
Group 1 Group 2 Group 3 Group 4 p*
Systolic blood pressure (mmHg)
Pre-HD 126.8±22.8 136.6±17.0 143.1±19.5 149.3±18.2 <0.01
T
� aabb
Post-HD 124.5±19.2 129.1±16.3 140.9±19.4 140.7±18.6 <0.01
T
� aabb
Diastolic blood pressure (mmHg)
Pre-HD 76.8±9.4 78.1±8.2 80.2±7.5 80.7±10.7 0.36
Post-HD 75.0±8.6 77.8±6.6 80.6±10.3 79.3±8.3 0.10
Heart rate (beats/min)
Pre-HD 50.5±16.3 60.0±15.0 64.2±16.7 68.6±14.6 <0.01
T
� aa ,  bb b
Post-HD 50.3±13.9 55.5±15.2 61.9±15.0 61.4±14.1 <0.02
T
� aa ,  bb b
Table 2. Comparison of blood pressure and heart rate among groups
*Statistical significance was tested by one-way analysis of variances among groups; 
�
The same letters indicate a difference not significant between
groups based on Turkey’s multiple comparison test.
Group 1 Group 2 Group 3 Group 4 p*
PTH 69.9±16.3 74.3±12.6 88.5±16.9 126.8±34.9 <0.01
T
� aa a b
Aldosterone
Pre-HD 418.0±130.6 272.6±84.9 67.1±7.4 91.6±18.5 <0.01
T
� aa a b
Post-HD 333.5±115.6 289.5±89.6 62.9±9.0 92.9±23.8 <0.01
T
� aa b b
Renin
Pre-HD 2.40±0.50 5.52±1.12 4.00±0.78 3.31±1.25 0.15
Post-HD 4.34±0.83 8.51±1.64 5.56±1.09 4.44±2.20 0.15
Aldosterone/renin ratio
Pre-HD 209.5±46.7 93.4±28.7 120.9±44.7 96.8±32.8 0.29
Post-HD 96.7±28.2 39.5±7.1 50.2±14.6 61.3±16.8 0.13
Epinephrine
Pre-HD 39.9±4.9 41.5±2.6 43.0±3.4 44.5±4.5 0.91
Post-HD 43.5±4.6 32.9±1.9 34.5±3.2 33.7±2.4 0.16
Norepinephrine
Pre-HD* 188.6±32.8 281.4±35.5 225.3±28.9 366.4±56.7 <0.05
T
� aa ,  b ab
Post-HD 161.5±32.5 149.8±26.1 136.9±19.5 226.9±60.8 0.31
Table 3. Comparison of concentrations of intact parathyroid hormone (PTH), renin, aldosterone, epinephrine, and norepinephrine among
groups
*Statistical significance was tested by one-way analysis of variances among groups; 
�
The same letters indicate a difference not significant between
groups based on Turkey’s multiple comparison test.608 Z.-R. Hong, H.-W. Gil, J.-O. Yang, et al.
(p=0.003; Table 4). NEP concentrations were significantly
lower in the patients who used the  -blocker compared to
those who did not (p<0.05). Pre- and post-HD NEP concen-
trations were significantly higher in patients who used mino-
xidil compared to those who did not (p<0.05; Table 4).
DISCUSSION
In the present study, the degree of intractability of BP con-
trol in HD patients was associated with pre- and post-HD
SBP, heart rate, Kt/V urea, pre- and post-HD aldosterone
concentrations, and pre-HD NEP concentrations. Of course,
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Fig. 2. Comparison of the concentration of intact parathyroid hor-
mone (PTH) among groups. Intact PTH concentrations were sig-
nificantly higher in Group 4 (*) compared to the other groups test-
ed by oneway analysis of variances (p<0.01) and Turkey’s multi-
ple comparison test.
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Fig. 3. Comparison of norepinephrine concentrations among gro-
ups. Norepinephrine concentrations prior to hemodialysis (pre-
HD) were significantly higher in Group 4 (*) than in Groups 1 and
3 tested by one-way analysis of variances (p<0.05) and Turkey’s
multiple comparison test.
*
*
ACEI Drug ARB Beta-blocker CCB Minoxidil
Renin
Pre-HD Absence 3.7±0.5 3.0±0.7 4.3±0.7 3.6±0.7 4.0±0.5
Presence 5.3±1.6 4.5±0.6 3.5±0.7 4.2±0.6 3.8±1.0
Post-HD Absence 5.9±0.8 5.2±1.1 6.4±0.9 6.1±1.0 6.1±0.8
Presence 6.5±2.1 6.4±0.9 5.3±1.1 5.9±1.0 5.3±1.6
Aldosterone
Pre-HD Absence 197.9±39.0 347.8±91.0
� 246.2±54.8 307.4±78.7
� 20.5.5±42.6
Presence 206.4±129.1 128.9±33.0 130.1±46.3 130.9±34.8 176.4±84
Post-HD Absence 185.2±38.5 316.4±91.7
� 229.8±54.3 262.3±69.0 194.4±42.0
Presence 181.7±104.5 122.6±28.4 118.8±38.1 135.8±38.7 150.1±69.0
Epinephrine
Pre-HD Absence 43.0±2.1 43.9±3.7 39.7±2.3 41.6±3.1 41.8±2.3
Presence 36.5±4.5 41.3±2.2 45.8±21.0 42.5±2.4 43.4±2.9
Post-HD Absence 36.8±1.9 40.1±3.6 36.9±19.4 39.2±2.9 36.6±2.1
�
Presence 29.7±2.8 33.8±1.8 34.3±15.2 33.7±2.1 32.9±1.5
Norepinephrine
Pre-HD Absence 255.3±19.9 239.3±33.4 216.6±21.9* 236.3±28.4 224.2±19.3
Presence 209.7±47.9 254.0±22.1 298.1±30.9 257.5±24.1 343.8±44.4
Post-HD Absence 154.9±15.1 144.7±20.6 142.2±16.2* 143.9±22.1 140.1±13.9
�
Presence 162.9±45.8 161.2±18.9 176.3±26.4 163.9±19.0 215.2±42.6
Aldosterone/renin ratio
Pre-HD Absence 139.3±25.4 176.0±33.0 143.8±31.1 161.3±32.6 137.3±27.3
Presence 69.7±25.9 106.5±28.6 107.7±30.2 109.2±29.7 99.2±25.5
Post-HD Absence 59.0±9.9 87.0±20.3* 57.4±11.2 69.3±16.1 55.9±9.5
Presence 54.4±17.2 44.7±8.3 59.8±14.4 51.3±10.1 67.6±22.4
Table 4. Effects of antihypertensive drugs on the concentrations of renin, aldosterone, epinephrine, and norepinephrine
Because drugs were prescribed after the commencement of HD, the pre- and post-HD values correspond to the values of the parameters in the ab-
sence and presence of each drug. *p<0.05; 
�
p<0.01.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.The Factors of Intractable Hypertension in Hemodialysis Patients 609
the associations between the aforementioned parameters and
the intractability of BP control do not necessarily mean these
factors were the cause of HT in these patients. SBP was higher
in those patients who required a greater number of different
antihypertensive drugs to control BP; this finding implies
that abnormally elevated BP was not controlled completely
in the HT patients in the present study.
There was no association between the degree of HT and
parameters such as body weight, interdialytic weight gain,
BMI, or amount of ultrafiltration during HD. To control the
HT of HD, first the patients should reach the target weight,
and if HT is not well controlled, the other factors should be
searched.
The value of Kt/V urea was significantly lower in Group
3 and 4 than Group 2 (Fig. 1). It suggests that the adequa-
cy of HD is an important factor to control HT. Interesting-
ly, aldosterone concentrations were lower in Groups 3 and 4
than in Groups 1 and 2, and aldosterone concentrations were
lower in patients who were treated with ARB and/or calcium
channel blockers. This result suggests that aldosterone could
be suppressed by hypertensive drugs in uncontrolled hyper-
tensive HD patients. HD, itself, seemed to have no effect on
the variation of renin and aldosterone because there was no
difference before and after HD. In the present study, NEP
concentrations were significantly higher in Group 4 than in
Groups 1 and 3 (Fig. 3), but there was no significant differ-
ence in the post-HD concentrations of NEP among the
groups. By contrast, there was a substantial individual vari-
ation in the changes in NEP concentrations before and after
HD, and there was no correlation between changes in NEP
concentrations and the degree of intractability of BP con-
trol. This suggests that NEP may be involved partly in HT
in HD patients.
We cannot explain why the apparent association between
plasma NEP concentrations and the degree of HT that was
observed prior to HD was no longer apparent after HD. How-
ever, it is worth noting that the process of HD can either
stimulate or suppress sympathetic activity. Some reports
showed that the plasma volume decreases during HD, which
can lead to an increase in plasma catecholamine concentra-
tions and in contrast, catecholamines are small molecules that
might be dialyzed and removed during HD (13-15). The
role of sympathetic activity on HT in hemodialysis was con-
troversial, but it seems to be that sympathetic activity is
individually involved in HT of HD patients. Minoxidil is
direct vasodilator. It induces a more marked activation of
adrenergic drive. However, our datas (Table 4) showed that
the patients prescribed with minoxidill had a the higher
concentration of EP and a lower concentration of NEP at
post-HD. The reasons might be that the patients on minox-
idil had other drugs including  -blocker. 
Interaction between renin and the hormones that regulate
calcium metabolism has been proposed to explain calcium-
induced vasoconstriction and sodium-sensitivity in HT pa-
tients (16). Raine and co-workers (17) reported higher intra-
cellular calcium concentrations within the platelets of ESRD
patients with elevated plasma concentrations of PTH com-
pared to patients with normal plasma concentrations of PTH;
moreover, they reported significant correlations between PTH
concentrations, platelet calcium concentrations, and mean
arterial BP. Similarly, hypercalcemia induced a greater increase
in BP in rats with ESRD than in normal rats (18). Such vas-
cular hyperresponsiveness can be reversed by parathyroidec-
tomy, which suggests that PTH plays an important role in
hypercalcemia-induced HT. In agreement with a previous
report, the intact PTH concentration in the present study
was significantly higher in Group 4 than in Groups 1-3,
which suggests that PTH is one of the factors that is involved
in the inability of ESRD patients to regulate BP effectively.
Previous reports indicated that the incidence of HT in EPO-
treated HD patients was 10-12% (19, 20). An increase in
total peripheral resistance is the primary cause of the increase
in BP in ESRD patients, while increased blood viscosity and
reversal of hypoxic vasodilation (21) have often been cited as
the main causes of the effects of EPO on total peripheral
resistance and BP (22-24). In the present study, we found no
significant difference in either the EPO dose or Hct and/or
Hb concentrations among the various groups. We thought
that EPO-induced hypertension could be controlled by hyper-
tensive drug, but further investigations are needed to prove
this.
Our study design had several limitations. First, we did not
examine all of the factors that have been implicated in the
development of HT in ESRD patients, such as arginine vaso-
pressin (25, 26), endothelial factors (27, 28), and natriuretic
peptides (29, 30). However, the aim of this study was not to
evaluate all the factors that are involved in HT, but rather
to elucidate which factor (s) may be responsible for HT in
ESRD patients. Second, antihypertensive drugs may stimu-
late the RAAS, sympathetic activity, and PTH. To reduce
such nonspecific effects, we evaluated parameters in patients
who were grouped based on their use of antihypertensive
drugs. Both pre- and post-HD aldosterone concentrations
were significantly lower in patients who used ARB, and pre-
HD aldosterone concentrations were significantly lower in
the patients who used calcium channel blockers. Because
aldosterone concentrations appeared to be influenced by the
antihypertensive drugs, this was not considered as a factor
that might be involved in HT. Third, our classification of
patients according to their use of antihypertensive drugs
does not mean that those factors that appeared to be associ-
ated with the degree of HT are necessarily the cause of HT.
Nevertheless, in practice, these factors should be addressed
as the first step in controlling HT in ESRD patients who
are undergoing HD.
In conclusion, we found that a low Kt/V urea, hyperpara-
thyroidism, and increased plasma NEP concentrations, rather
than traditional causes of HT, could be associated with the610 Z.-R. Hong, H.-W. Gil, J.-O. Yang, et al.
intractability of BP control in ESRD patients who under-
went HD.
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